YSPSL

Drug Profile

YSPSL

Alternative Names: PSGL-1Ig; Recombinant P-selectin glycoprotein ligand-1 fusion protein; rPSGL-Ig

Latest Information Update: 11 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Wyeth; Ys Therapeutics
  • Class Anti-inflammatories; Anti-ischaemics; Antithrombotics; Recombinant fusion proteins
  • Mechanism of Action P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Deep vein thrombosis; Delayed graft function; Inflammation; Myocardial infarction; Ocular inflammation; Renal transplant rejection; Reperfusion injury; Sickle cell anaemia; Thrombosis

Most Recent Events

  • 11 Sep 2015 Discontinued - Phase-I/II for Delayed graft function (Prevention) in USA (IV)
  • 11 Sep 2015 Discontinued - Phase-II for Reperfusion injury (Prevention) in USA (IV)
  • 11 Sep 2015 Discontinued for Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top